REVELATION BIOSCIENCES, INC. REVB
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury ("AKI") and GEM-CKD as a treatment for chronic kidney disease ("CKD"). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.
Our common stock and warrants sold in our initial public offering ("Public Warrants") are listed on The Nasdaq Stock Market, LLC ("Nasdaq") under the ticker symbol "REVB" and "REVBW," respectively.
On June 23, 2025, at the annual meeting of stockholders, our stockholders granted discretionary authority to our board of directors to (i) amend our certificate of incorporation one or more times to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a "reverse stock split," at a specific ratio within a range of one-for-two to a maximum of a one-for-250 split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split(s), if at all, within one year of the date the proposal is approved by stockholders
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $4.1M | $3.5M | $4.1M | $5.4M | $6.9M | — | — |
| SG&A | $5.0M | $4.4M | $4.5M | $5.5M | $5.0M | $145.5K | — |
| Total operating expenses | $9.1M | $8.0M | $8.7M | $10.9M | $12.0M | $145.5K | — |
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | -$12.0M | — | — |
| Interest expense | — | — | — | — | $41.8K | — | — |
| Pre-tax income | -$8.9M | -$15.0M | -$120.3K | -$10.8M | -$12.0M | -$1.6M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$8.9M | -$15.0M | -$120.3K | -$10.8M | -$12.0M | -$1.6M | -$3.6K |
| EPS, basic | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 | -0.68 | — |
| EPS, diluted | -23.95 | -1,052.16 | -8.44 | -149.20 | -42.50 | -0.68 | — |
| Shares, diluted (wtd. avg.) | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 | 2.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.7M | $6.5M | $12.0M | $5.3M | $1.3M | $4.5M | — |
| Short-term investments | — | — | — | — | — | $525.3K | — |
| Total current assets | $10.8M | $6.6M | $12.1M | $5.4M | $1.9M | $651.3K | $22.7K |
| Property, plant and equipment | $18.1K | $56.3K | $65.1K | $90.1K | $115.2K | — | — |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M | $74.2M | $22.7K |
| Accounts payable | $577.5K | $783.6K | $1.4M | $554.2K | $596.3K | $33.8K | — |
| Total current liabilities | $2.0M | $1.9M | $5.6M | $4.5M | $2.1M | $3.4M | $26.3K |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M | $6.3M | $26.3K |
| Retained earnings | -$49.4M | -$40.5M | -$25.5M | -$25.3M | -$14.5M | -$5.7M | -$3.6K |
| Total equity | $8.9M | $4.7M | $6.6M | $1.1M | -$99.5K | $3.4M | -$3.6K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M | -$216.7K | — |
| Depreciation and amortisation | $27.1K | $27.9K | $25.0K | $25.0K | $16.8K | — | — |
| Stock-based compensation | $595.4K | $168.8K | $155.7K | $301.1K | $470.9K | — | — |
| Capital expenditure | — | $19.2K | — | — | $132.0K | — | — |
| Investing cash flow | — | -$19.2K | — | — | -$132.0K | -$74.0M | — |
| Financing cash flow | $12.5M | $12.8M | $14.0M | $15.2M | $8.0M | $74.3M | — |
| Buybacks | — | — | — | — | $35.5M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-076552.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | -$3.6K | -$1.6M | -$12.0M | -$10.8M | -$120.3K | -$15.0M | -$8.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Charter or fiscal year changed Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Shareholder rights changed Item 3.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |